AGNES: Arrhythmia Genetics in the NEtherlandS
Study Details
Study Description
Brief Summary
The AGNES case-control set consists of individuals with a first acute ST-elevation myocardial infarction. AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction. AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation. All cases and controls are recruited at seven heart centers in The Netherlands. The investigators' exclude individuals with an actual non-ST-elevation myocardial infarction, prior myocardial infarction, congenital heart defects, known structural heart disease, severe comorbidity, electrolyte disturbances, trauma at presentation, recent surgery, previous coronary artery bypass graft or use of class I and III antiarrhythmic drugs. Individuals who develop ventricular fibrillation during or after percutaneous coronary intervention are not eligible. Furthermore, because early reperfusion limits the opportunity of developing ventricular fibrillation, potential control subjects undergoing percutaneous coronary intervention within 2 h after onset of myocardial ischemia symptoms were not included. This time interval is based on the observation that >90% of cases develop ventricular fibrillation within 2 h after onset of the complaint of symptoms.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| AGNES Controls AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation. |
|
| AGNES cases AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction. |
Outcome Measures
Primary Outcome Measures
- Differences in genetic and inflammatory profile between cases and controls. [Immediately upon admission, measures are based on samples taken at admission.]
Differences in genetic profile and inflammatory profile between cases and controls are investigated between the complete cohorts.
Secondary Outcome Measures
- Differences in clinical characteristics between cases and controls [Immediately upon admission, measures are based on status at hospital admission.]
Differences in clinical characteristics between cases and controls are investigated between the complete cohorts.
Other Outcome Measures
- Previously described risk factors [Immediately upon admission, measures are based on status at hospital admission.]
Clinical characteristics that were previously described as possible risk factors for the development of VF (ventricular Fibrillation) during AMI (acute myocardial infarction): certain ECG characteristics, infarct size, infarct location, extent and localization of coronary disease. Are investigated for differences between cases and controls in the complete cohorts
Eligibility Criteria
Criteria
Inclusion Criteria:
-
First ST elevation myocardial infarction (STEMI)
-
Between 18 and 80 years old
Exclusion Criteria:
-
A grandparent from non-European descent
-
Inborn errors; congenital heart defects.
-
Prior myocardial infarction (either STEMI or non-STEMI)
-
Previous CABG (coronary artery bypass graft)
-
Use of anti-arrhythmic drugs with the exception of beta-blockers, Ca2+-antagonists and lanoxin.
-
Severe current co morbidity (electrolyte disturbances, K+>5.5, K+<3.0 mmol/L, anaemia, trauma, surgery).
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- CCMO # 13598